# OnCo record larotrectinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix owl: .
@prefix xsd: .
a schema:Drug ;
onco:kind "drug" ;
schema:identifier "larotrectinib" ;
schema:name "Larotrectinib"@en ;
schema:description "The first drug approved for a gene fusion regardless of where the cancer started; it works in about 75% of NTRK-fusion cancers, from infant fibrosarcoma to salivary and thyroid cancers."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:sameAs ;
owl:sameAs ;
schema:citation , , , ;
onco:status "approved" ;
onco:tag "gap-fill" ;
onco:modality "Small-molecule pan-TRK inhibitor (first generation)" ;
schema:alternateName "Vitrakvi" ;
onco:approval "US 2018: Solid tumours with NTRK gene fusion without known acquired resistance mutation, metastatic or unresectable, adults and children", "EU 2019: Same", "UK 2020: NTRK fusion-positive solid tumours in adults and children, locally advanced or metastatic or where surgery would cause severe morbidity, with no satisfactory treatment options: NICE TA630 (27 May 2020) recommends it within the Cancer Drugs Fund under a managed access agreement", "England (NICE) 2020: NTRK fusion-positive solid tumours, including colorectal cancer" ;
onco:acceleratedApproval "US 2018-11-26: Treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment", "US 2018-11-26: Formation: Treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment" ;
onco:acceleratedApprovalConfirmed "US 2025-04-09: Treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment", "US 2025-04-09: Formation: Treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment" ;
onco:related ;
onco:cancers , , , , , , , ;
onco:technologies , ;
onco:targets ;
onco:companies ;
onco:terms , ;
onco:trials ;
onco:keyPapers .